Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ADAM7 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM32 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 32 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM33 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 33 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM5 Biologics Sequence Review Report 2026: Putative disintegrin and metalloproteinase domain-containing protein 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
10 min read
Spontaneous bacterial peritonitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Spontaneous bacterial peritonitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Refractory ascites Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Refractory ascites indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Minimal hepatic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Minimal hepatic encephalopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Crigler-Najjar syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Crigler-Najjar syndrome type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 5 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 5 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Latest Hotspot
10 min read
Congenital portosystemic shunt Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Congenital portosystemic shunt strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Classic galactosemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Classic galactosemia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 4 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.